Hence, this study aimed to investigate whether NSCLC patients lacking driver gene mutations, classified as M1c1 or M1c2, and treated with first‐line PD‐1/PD‐L1 inhibitors combined with chemotherapy, exhibit divergent prognoses. Here, PDCD1 is linked to non-small cell lung carcinoma.